Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer
-
Published:2024-09
Issue:9
Volume:42
Page:1598-1613.e4
-
ISSN:1535-6108
-
Container-title:Cancer Cell
-
language:en
-
Short-container-title:Cancer Cell
Author:
Xu Jiachen, Wan Rui, Cai Yiran, Cai Shangli, Wu Lin, Li Baolan, Duan Jianchun, Cheng Ying, Li Xiaoling, Wang Xicheng, Han Liang, Wu Xiaohong, Fan Yun, Yu Yan, Lv Dongqing, Shi Jianhua, Huang Jianjin, Zhou Shaozhang, Han Baohui, Sun Guogui, Guo Qisen, Ji Youxin, Zhu Xiaoli, Hu Sheng, Zhang Wei, Wang Qiming, Jia Yuming, Wang Ziping, Song Yong, Wu Jingxun, Shi Meiqi, Li Xingya, Han Zhigang, Liu Yunpeng, Yu Zhuang, Liu An-Wen, Wang Xiuwen, Zhou Caicun, Zhong Diansheng, Miao Liyun, Zhang Zhihong, Zhao Hui, Yang Jun, Wang Dong, Wang Yingyi, Li Qiang, Zhang Xiaodong, Ji Mei, Yang Zhenzhou, Cui Jiuwei, Gao Beili, Wang Buhai, Liu Hu, Nie Lei, He Mei, Jin Shi, Gu Wei, Shu Yongqian, Zhou Tong, Feng Jian, Yang Xinmei, Huang Cheng, Zhu Bo, Yao Yu, Yu Jianjun, Yao Sheng, Shen Runxi, Wang ZhijieORCID, Wang Jie
Reference58 articles.
1. Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407;Paz-Ares;Ann. Oncol.,2019 2. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial;Zhou;Lancet Respir. Med.,2021 3. Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01);Wang;J. Clin. Oncol.,2023 4. The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer;Ezeife;Ther. Adv. Med. Oncol.,2022 5. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial;Kim;Nat. Med.,2022
|
|